Acrux Limited is an Australia-based pharmaceutical company. The Company is engaged in the development and commercialization a portfolio of generic topical prescription pharmaceutical products, which uses dermal and transdermal drug delivery technology. The Company’s commercialized products include Lenzetto, Evamist and Testosterone Topical Solution. Its Lenzetto is available in approximately 30 countries across the European Union and other markets in the Middle East and Africa. Its estradiol spray is available for sale in the United States where the product is marketed under the Evamist brand. Its Abbreviated New Drug Application (ANDA) for generic topical testosterone solution, 30mg/1.5mL and the Company sells, markets and distributes agreement in the United States. The Company’s pipeline candidates include Jublia, EMLA and Aczone 7.5% Gel. The Company is developing Jublia for the treatment of fungal infection of the nail. It is developing EMLA for the treatment of topical anesthetic.